This report analyzes the disruptive themes that have driven M&A activity in Q3 2024 in the pharma Sector.
The global pharma sector in Q3 2024 witnessed deals worth $35 billion, a decline of 3% compared to Q3 2023. In terms of deal volume, there was a rise of 11% to record 279 M&A deals in Q3 2024. The Pharma sector recorded 12 mega deals (defined as any deal valued at more than $1 billion) in Q3 2024, an increase of 71% compared to Q3 2023.
The global pharma sector in Q3 2024 witnessed deals worth $35 billion, a decline of 3% compared to Q3 2023. In terms of deal volume, there was a rise of 11% to record 279 M&A deals in Q3 2024. The Pharma sector recorded 12 mega deals (defined as any deal valued at more than $1 billion) in Q3 2024, an increase of 71% compared to Q3 2023.
Scope
- This report provides an overview of merger and acquisition activity globally in Q3 2024 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q3 2024 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of Pharma M&A Market - Q3 2024
- Top Pharma M&A Deals by Sector - Q3 2024
- Pharma M&A Deals Analysis by Geography - Q3 2024
- Top Themes Driving Pharma M&A Activity - Q3 2024
- Appendix 1: Deal Selection Criteria
- Appendix 2: Top Themes for 2024 in Pharma
- Appendix 3: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Genentech USA
- Haleon
- Keen Vision Acquisition
- Medera
- McKesson Corp
- CBC Group
- Mubadala Investment Co
- Repligen
- Merck & Co
- Recursion Pharma
- Exscientia
- Nestle Health Science
- CVC Capital Partners Fund IX
- China Resources Sanjiu Medical & Pharmaceutical
- Otsuka America
- Boehringer Ingelheim International
- Collegium Pharmaceutical
- Mankind Pharma
- Agilent Technologies
- Macquarie Asset Management Holding
- Eli Lilly and Co
- Quest Diagnostics
- Partners Group
- Curon Biopharma
- Tianjin TSKF Pharmaceutical
- Community Oncology Revitalization Enterprise Ventures
- Maravai LifeSciences Holdings
- Tasly Pharmaceutical Group
- Jnana Therapeutics
- Nerio Therapeutics
- Ironshore Therapeutics
- Bharat Serums And Vaccines
- BioVectra
- Geneuone Science
- Morphic Holding
- LifeLabs
- FairJourney Biologics
- UCB
- Regor Pharma
- Seres Therapeutics
- Mallinckrodt
